Highly elevated serum CA-125 levels in patients with non-malignant gynecological diseases

Purposes To identify patients with highly elevated serum CA-125 levels and analyze their clinical characteristics.

Patients with non-malignant gynecologic disease (NMGDs, n = 41), in whom serum CA-125 levels were over 1,000 IU/ml were retrospectively enrolled in the study. Seventy-one patients with epithelial ovarian cancer (EOC), in whom, serum CA-125 levels were over 1,000 IU/ml were included as the comparison group. Clinical parameters were compared between the two groups.

In NMGDs group, 43.90% of the patients had endometriosis. The median of serum CA-125 level in NMGDs was much lower than that of EOC subjects (P < 0.001). Compared to EOC group, the patients in NMGDs group were much younger (P < 0.001) and had fewer histories of pelvic masses (P < 0.001) but had more clinical complaints such as acute abdominal symptoms (P < 0.001) and/or abnormal vaginal bleeding (P = 0.022). Clinical progresses of these two groups were correlated with changes of serum CA-125 levels by follow-up for up to 386 days.

High levels of serum CA-125 were found not only in the EOC, but also in some NMGDs, especially in the reproductive patients with complaints of acute abdomen symptoms or abnormal vaginal bleeding.

Chu CS, Rubin SC (2006) Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 20:307–320 Rosenthal AN, Menon U, Jacobs IJ (2006) Screening for ovarian cancer. Clin Obstet Gynecol 49:433–447 Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10:327–340 Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR, Buys SS (2009) Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 113:775–782 Grover S, Koh H, Weideman P, Quinn MA (1992) The effect of the menstrual cycle on serum CA 125 levels: a population study. Am J Obstet Gynecol 167:1379–1381 Kobayashi F, Takashima E, Sagawa N, Mori T, Fujii S (1993) Maternal serum CA125 levels in early intrauterine and tubal pregnancies. Arch Gynecol Obstet 252:185–189 Buamah P (2000) Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol 75:264–265 Van Calster B, Timmerman D, Bourne T, Testa AC, Van Holsbeke C, Domali E, Jurkovic D, Neven P, Van Huffel S, Valentin L (2007) Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 99:1706–1714 Ghaemmaghami F, Karimi ZM, Hamedi B (2007) High levels of CA125 (over 1,000 IU/ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review. Arch Gynecol Obstet 276:559–561 Muyldermans M, Cornillie FJ, Koninckx PR (1995) CA125 and endometriosis. Hum Reprod Update 1:173–187 Johansson J, Santala M, Kauppila A (1998) Explosive rise of serum CA 125 following the rupture of ovarian endometrioma. Hum Reprod 13:3503–3504 Buyukbayrak EE, Ozyapi AG, Karsidag YK, Pirimoglu ZM, Unal O, Turan C (2008) Imperforate hymen: a new benign reason for highly elevated serum CA 19.9 and CA 125 levels. Arch Gynecol Obstet 277:475–477 Acknowledgments This work was financially supported by Research Grants from Key research program of Education of Zhejiang Province, China (No. 20061426) and National Science Foundation of China (No. 30700273). Conflict of interest The authors declare that they have no competing interests. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article He, RH., Yao, WM., Wu, LY. et al. Highly elevated serum CA-125 levels in patients with non-malignant gynecological diseases. Arch Gynecol Obstet 283 (Suppl 1), 107–110 (2011). https://doi.org/10.1007/s00404-010-1717-5 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s00404-010-1717-5